# Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02465515` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02465515](<https://clinicaltrials.gov/study/NCT02465515>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02465515

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 9463 participants.

## Technical summary

Registry record NCT02465515. Randomized; quadruple masking; primary purpose treatment. Start 2015-07-01 (actual); primary completion 2018-02-20 (actual). Results posted on 2019-03-06.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 9463 participants (enrolled count; ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Started: 2015-07-01 (actual) (ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Primary completion: 2018-02-20 (actual) (ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Completion: 2018-03-14 (actual) (ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Results first posted: 2019-03-06 (ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Countries: United States; Argentina; Belgium; Bulgaria; Canada; Czechia; Denmark; France; Germany; Greece; Hong Kong SAR China; Hungary; Italy; Mexico; Netherlands; Norway; Peru; Philippines; Poland; Russia; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02465515, source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02465515-2019-03-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus
- Intervention (Biological): Albiglutide 30 mg
- Intervention (Biological): Albiglutide 50 mg
- Intervention (Biological): Albiglutide matching placebo
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY
- Collaborator: Duke Clinical Research Institute
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)
- Registry lists this organization as a collaborator: Duke Clinical Research Institute (`cardio:org-duke-clinical-research-institute`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (`cardio:pubmed-30291013`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial (`cardio:pubmed-38317618`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f3ecd7fd5fb3cec5ba5873801952129968966b6b55e93fc4ba528dcf0c153a35
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
